BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32569329)

  • 1. The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study.
    Dalhammar K; Malmström M; Schelin M; Falkenback D; Kristensson J
    PLoS One; 2020; 15(6):e0235045. PubMed ID: 32569329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care utilization among patients with oesophageal and gastric cancer: the impact of initial treatment strategy and assignment of a contact nurse.
    Dalhammar K; Malmström M; Sandberg M; Falkenback D; Kristensson J
    BMC Health Serv Res; 2021 Sep; 21(1):1019. PubMed ID: 34579714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life one year after the diagnosis of oesophageal cancer: a population-based study from the Swedish National Registry for Oesophageal and Gastric Cancer.
    Sunde B; Lindblad M; Malmström M; Hedberg J; Lagergren P; Nilsson M
    BMC Cancer; 2021 Nov; 21(1):1277. PubMed ID: 34836512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study.
    Kempf E; Tournigand C; Rochigneux P; Aubry R; Morin L
    Eur J Cancer; 2017 Jul; 79():31-40. PubMed ID: 28458120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old age as risk indicator for poor end-of-life care quality - a population-based study of cancer deaths from the Swedish Register of Palliative Care.
    Lindskog M; Tavelin B; Lundström S
    Eur J Cancer; 2015 Jul; 51(10):1331-9. PubMed ID: 25958036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptoms, problems and quality of life in patients newly diagnosed with oesophageal and gastric cancer - a comparative study of treatment strategy.
    Dalhammar K; Kristensson J; Falkenback D; Rasmussen BH; Malmström M
    BMC Cancer; 2022 Apr; 22(1):434. PubMed ID: 35448961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Geographical differences in cancer treatment and survival for patients with oesophageal and gastro-oesophageal junctional cancers.
    Jestin Hannan C; Linder G; Kung CH; Johansson J; Lindblad M; Hedberg J
    Br J Surg; 2020 Oct; 107(11):1500-1509. PubMed ID: 32484241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical decline and its implications in the management of oesophageal and gastric cancer: a systematic review.
    O'Neill L; Moran J; Guinan EM; Reynolds JV; Hussey J
    J Cancer Surviv; 2018 Aug; 12(4):601-618. PubMed ID: 29796931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer patients hospitalised in the last week of life risk insufficient care quality - a population-based study from the Swedish Register of Palliative Care.
    Elmstedt S; Mogensen H; Hallmans DE; Tavelin B; Lundström S; Lindskog M
    Acta Oncol; 2019 Apr; 58(4):432-438. PubMed ID: 30633611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care.
    Lindemann K; Martinsson L; Kaasa S; Lindquist D
    Acta Oncol; 2020 Jun; 59(6):636-643. PubMed ID: 32238040
    [No Abstract]   [Full Text] [Related]  

  • 11. Better quality of end-of-life care for persons with advanced dementia in nursing homes compared to hospitals: a Swedish national register study.
    Martinsson L; Lundström S; Sundelöf J
    BMC Palliat Care; 2020 Aug; 19(1):135. PubMed ID: 32847571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of end-of-life care in patients with dementia compared to patients with cancer: A population-based register study.
    Martinsson L; Lundström S; Sundelöf J
    PLoS One; 2018; 13(7):e0201051. PubMed ID: 30059515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hospital of diagnosis influences the probability of receiving curative treatment for oesophageal and gastric cancer].
    van Putten M; Verhoeven RHA; Koëter M; van Laarhoven HWM; van Sandick JW; Plukker JTM; Siersema PD; Hulshof MCCM; Wijnhoven BPL; Lemmens VEPP; Nieuwenhuijzen GAP
    Ned Tijdschr Geneeskd; 2018; 162():D1970. PubMed ID: 29600921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality indicators for oesophageal and gastric cancer: a population-based study in Belgium, 2004-2008.
    Stordeur S; Vlayen J; Vrijens F; Camberlin C; De Gendt C; Van Eycken E; Lerut T
    Eur J Cancer Care (Engl); 2015 May; 24(3):376-86. PubMed ID: 25565040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient education-level affects treatment allocation and prognosis in esophageal- and gastroesophageal junctional cancer in Sweden.
    Linder G; Sandin F; Johansson J; Lindblad M; Lundell L; Hedberg J
    Cancer Epidemiol; 2018 Feb; 52():91-98. PubMed ID: 29278841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International benchmarking in oesophageal and gastric cancer surgery.
    Busweiler LAD; Jeremiasen M; Wijnhoven BPL; Lindblad M; Lundell L; van de Velde CJH; Tollenaar RAEM; Wouters MWJM; van Sandick JW; Johansson J; Dikken JL
    BJS Open; 2019 Feb; 3(1):62-73. PubMed ID: 30734017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
    Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
    Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of 5α-reductase inhibitors and survival of oesophageal and gastric cancer in a nationwide Swedish cohort study.
    Rabbani S; Mattsson F; Lagergren J; Xie S
    Acta Oncol; 2023 May; 62(5):438-443. PubMed ID: 37216488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.
    Adamson D; Byrne A; Porter C; Blazeby J; Griffiths G; Nelson A; Sewell B; Jones M; Svobodova M; Fitzsimmons D; Nixon L; Fitzgibbon J; Thomas S; Millin A; Crosby T; Staffurth J; Hurt C
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):292-303. PubMed ID: 33610215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverging trends in recent population-based survival rates in oesophageal and gastric cancer.
    Lagergren J; Mattsson F
    PLoS One; 2012; 7(7):e41352. PubMed ID: 22815994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.